Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
Name:
PIIS147020451930395X.pdf
Size:
417.8Kb
Format:
PDF
Description:
Full text, Open Access article
Authors
de Boer, SPowell, M
Mileshkin, L
Katsaros, D
Bessette, P
Haie-Meder, C
Ottevanger, P
Ledermann, J
Khaw, P
Colombo, A
Fyles, A
Baron, M
Jürgenliemk-Schulz, I
Kitchener, Henry C
Nijman, H
Wilson, G
Brooks, S
Carinelli, S
Provencher, D
Hanzen, C
Lutgens, L
Smit, V
Singh, N
Do, V
D'Amico, R
Nout, R
Feeney, A
Verhoeven-Adema, KW
Putter, H
Creutzberg, C
Affiliation
Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands.Issue Date
2018-03
Metadata
Show full item recordAbstract
Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer.Citation
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. 2018, 19 (3):295-309 Lancet Oncol.Journal
The Lancet. OncologyDOI
10.1016/S1470-2045(18)30079-2PubMed ID
29449189Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(18)30079-2